TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is a male or non-pregnant female 18 years of age or older.~2. Subject has provided written informed consent.~3. Subject has a clinical diagnosis of stable mild to moderate plaque psoriasis for at least two months.~4. Females must be post-menopausal, surgically sterile, or use an effective method of birth control. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 2/Baseline.~5. Males (or their female partner) must agree to use an effective method of birth control throughout the study.~6. Subject has two similar contralateral Target Plaques.~7. Subject is willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.~8. Subject, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation of the plaque psoriasis or exposes the subject to an unacceptable risk by study participation.~Exclusion Criteria:~1. Subject is pregnant, lactating, or is planning to become pregnant during the study.~2. Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.~3. Subject has guttate, pustular, erythrodermic, inverse, or other non-plaque forms of psoriasis.~4. Subject has psoriasis beyond the two Target Plaques that, in the investigator's opinion, could not be reasonably managed with only a bland emollient during the study.~5. Subject is currently enrolled in an investigational drug or device study.~6. Subject has been previously enrolled in this study and treated with test article.~Other protocol-defined inclusion and exclusion criteria assessed by the study staff may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DUR-928 Topical Solution (Type: EXPERIMENTAL): DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
- Vehicle Topical Solution (Type: PLACEBO_COMPARATOR): Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged 15 years and over (≥18 years in United Kingdom and South Africa), with at least a 12 month documented history of experiencing migraine according to IHS criteria, including confirmation of a 3 month diary based documented history of MAM.~* An average frequency of MAM in at least two out of three menstrual cycles, within the previous 12 months~* Regular, predictable menstrual periods~* MAM headaches occurring between Day -2 and day +4 of menses~* Able and willing to sign informed consent and to comply with study procedures, including completion of the diary cards.~Exclusion Criteria:~* More than three migraine attacks per month that were not MAM attacks~* A history of myocardial infarction, ischemic heart disease (or presenting with symptoms or signs compatible with ischemic heart disease), coronary vasospasm or peripheral vascular disease~* Significant cerebrovascular disease including basilar or hemiplegic migraine~* Uncontrolled hypertension (SBP \>180 mmHg, DBP \>95 mmHg)~* Severe hepatic or renal insufficiency~* More than 15 headache days per month, exclusive of migraine headache~* Any other condition or serious illness which, in the opinion of the investigator, would interfere with optimal participation in the study~* A history of clinically relevant allergy, including that to frovatriptan or other triptans~* Pregnant or breast-feeding, or intending to become pregnant or breast-feed during the study period (patients were to be using adequate contraception and have a negative pregnancy test at screening)~* Treatment with another investigational drug within 30 days or 5 half-lives (whichever was longer) before the screening visit~* Any change in their oral contraceptive medication (if applicable) in the 2 months prior to screening, or anticipation of any change during study participation~* Any change in the type or dose of any prophylactic migraine medication in the 2 months prior to screening, or anticipation of any change during study participation~* A history of migraine with aura, according to IHS criteria, and currently treated with a combined oral contraceptive (South Africa only).

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Frovatriptan 2.5 mg (Type: EXPERIMENTAL): Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* You must have been diagnosed with schizophrenia or schizoaffective disorder~* You must be able to visit the doctor's office once every two weeks for three months, then once every four weeks for the next three months with a possible bi-weekly visit during the fifth month~* If you are currently taking a medication for schizophrenia or schizoaffective disorder, you have been taking it for at least 30 days without any changes~* If you are a female, you must have a negative pregnancy test and be using an effective method of contraception~Exclusion Criteria:~* You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack, stroke, uncontrolled seizures, serious infection, unstable heart disease (such as ischemic heart disease or congestive heart failure), an uncorrected narrow angle glaucoma or human immunodeficiency virus (HIV)~* You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine systems, or blood~* You have a diagnosis of an eating disorder~* You have a history of Parkinson's Disease or any related disorders~* You are allergic to sulfa drugs or any of the medications involved in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): olanzapine plus behavioral information
- Olanzapine + Amantadine (Type: EXPERIMENTAL): Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
- Olanzapine + Metformin (Type: EXPERIMENTAL): Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* upper age to 18 years~* mammary adenocarcinoma nonmetastatic and histologically proven~* wait under an adjuvant or neoadjuvant chemotherapy according to the following conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100 (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500 or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3 cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++~* Patient with the capacity/faculties to understand a newsletter and sign an informed consent~* Patient receiving social coverage~* Patient who can be treated and followed in the center for a period of at least one year~* WHO scale 0 or 1~Exclusion Criteria:~* Age below 18 years~* Diseases of the scalp or whatever hair-showing against helmet or alopecia~* Using pre nail resin before and per chemotherapy~* mammary adenocarcinoma stage IV~* Indication of docetaxel for cancer of another organ than breast~* Treatment processing or programmed during chemotherapy with an innovative molecule being evaluated~* Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia.~* Uncontrolled severe arterial disease.~* Presence of a device\> grade 1 neuropathy before the start of chemotherapy~* Patient unable to submit the protocol followed for psychological, social, family or geographical~* Patient with an incompatible underlying disease or concomitant with the inclusion in the trial, whether psychiatric or somatic~* Patient trust, guardianship, under legal protection measure, deprived of freedom~* Male~* Criteria for non randomization (before the first course of docetaxel) :~  * Presence of peripheral neuropathy\> grade 1 after the first 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.~ * Presence of a nail or skin toxicity\> grade 1 after 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard cryoprotection (Type: ACTIVE_COMPARATOR): Proposal helmet without mittens and booties
- Cryoprotection with mittens and booties (Type: EXPERIMENTAL): Standard cryoprotection with mittens and booties

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be at least 18 years of age at the time of signing the informed consent.~* Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of the CNS.~* Male and female.~* Estimated glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m\^2.~Exclusion Criteria:~* Considered clinically unstable or has a concomitant/intercurrent condition (e.g. COVID-19 infection) that would not allow participation for the full planned study period (i.e. period 1, 2 or both) in the judgement of the investigator.~* Severe cardiovascular disease.~* Patients undergoing liver transplantation.~* Any contraindication to MRI examinations.~* History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents, foods, chemicals or other substances.~* History of allergic asthma and/ or atopic dermatitis.~* Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI:~  * Lepto-meningeal disease (e.g. leptomeningeal carcinomatosis). Dural lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded~ * Pituitary adenomas (macro and micro)~ * Tumors of the choroid plexus~ * Tumors of the pineal gland~ * Dermoid/epidermoid tumors~ * Infectious disease (e.g. brain abscess, cisticercosis, etc.)~ * Venous angiomas~ * Subacute/chronic ischemia~ * Encephalitis~ * Multiple sclerosis (acute and chronic)~ * Optic neuritis~ * Chordomas~ * Von Hippel Lindau syndrome~ * Hypertensive leukoencephalopathy.~* Receipt of any contrast agent \< 72 h prior to the study MRIs, or planned receipt of any contrast agent within 72 h after the second study MRI.~* Planned or expected biopsy in the region of interest or any interventional therapeutic procedure from the first study MRI up to 24 h after the second study MRI.~* Planned or expected change in any treatment or procedure between the two study MRIs that may alter image comparability and /or chemotherapy which is changed between the two MRI procedures.~* Contraindications to the administration of gadobutrol, as specified in the local product label.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol + Gadoquatrane (Type: EXPERIMENTAL): Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of Gadoquatrane (BAY1747846).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects 5 to 20 years of age, inclusive, at Screening~2. Body weight ≥12 kg at Screening~3. Can swallow the study medication provided as a liquid solution or can take it by gastrostomy tube~4. Has classic/typical Rett syndrome (RTT)~5. Has a documented disease-causing mutation in the MECP2 gene~6. Has a stable pattern of seizures, or has had no seizures, within 8 weeks of Screening~7. Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter or must agree to use acceptable methods of contraception. Subject must not be pregnant or breastfeeding.~8. The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments~9. Subject and caregiver(s) must reside at a location to which study drug can be delivered and have been at their present residence for at least 3 months prior to Screening~Exclusion Criteria:~1. Has been treated with insulin within 12 weeks of Baseline~2. Has current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or has major surgery planned during the study~3. Has a history of, or current, cerebrovascular disease or brain trauma~4. Has significant, uncorrected visual or uncorrected hearing impairment~5. Has a history of, or current, malignancy~6. Has a known history or symptoms of long QT syndrome~Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and condition do not meet all pre-specified entry criteria).

- Gender: FEMALE
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Drug - Trofinetide (Type: EXPERIMENTAL): Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
- Placebo (Type: PLACEBO_COMPARATOR): Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant and/or his parent/legal guardian is willing and able to provide signed informed consent, and the participant, if less than (\<) 18 years of age, is willing to provide assent if deemed able to do so~* Participant is male and has been treated with agalsidase alfa at 0.2 mg/kg q2w for the 12 months prior to switching to agalsidase beta~* The participant has a confirmed diagnosis of Fabry disease by alfa-galactosidase A (alfa-GAL) activity and/or genotyping per local standards~* The participant when switched to agalsidase beta receives the labeled dose, that is, 0.9 to 1.1 mg/kg (1 mg/kg) q2w, and must be willing to maintain the labeled dose for the duration of the study~Exclusion Criteria:~* The participant is on dialysis or is post renal transplantation~* The participant is in end-stage cardiac failure~* The participant and/or his parent or legal guardian, in the opinion of the investigator, is unable to adhere to the requirements of the study~* The participant has been switched from agalsidase alfa to agalsidase beta and does not have historical blood and urine samples

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Agalsidase beta (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Substitution After Upper Gastro-Intestinal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Acute upper gastrointestinal bleeding~* Anemia~Exclusion Criteria:~* Liver disease~* Terminal cancer~* Kidney disease~* variceal bleeding~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous iron (Type: ACTIVE_COMPARATOR): None
- Oral iron (Type: ACTIVE_COMPARATOR): None
- Isotonic Sodium and placebo tablets (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lactobacillus Reuteri in Adult With Functional Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* functional constipation rome III~Exclusion Criteria:~* hypothyroidism or other metabolic or renal abnormalities, or~* antibiotic's treatment,~* probiotic or prebiotic supplementation in the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- lactobacillus reuteri (Type: EXPERIMENTAL): Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
- placebo (Type: PLACEBO_COMPARATOR): a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MRI for Non-invasive Evaluation of Brain Stress

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients presenting to the Plastic Surgery or Neurosurgery clinics with scheduled sedated MRI and abnormalities such as hydrocephalus (and possibly some patients to be used as controls who present to the clinic with no known skull or brain abnormalities)~Exclusion Criteria:~* history of abnormalities known to affect brain topology or function~* implants (e.g. pacemakers) that might rule out use of MR scanning.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- craniofacial abnormalities (Type: EXPERIMENTAL): Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).~* Individuals, 18 years of age or older, willing to provide consent may be eligible for the SCORE Study.~Exclusion Criteria: refer to SCORE Study website at https://web.emmes.com/study/score/ for listing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRVO Observation (Type: ACTIVE_COMPARATOR): None
- CRVO 1 mg dose triamcinolone acetonide (Type: ACTIVE_COMPARATOR): None
- CRVO 4 mg dose triamcinolone acetonide (Type: ACTIVE_COMPARATOR): None
- BRVO standard care (Type: ACTIVE_COMPARATOR): None
- BRVO 1 mg dose triamcinolone acetonide (Type: ACTIVE_COMPARATOR): None
- BRVO 4 mg dose triamcinolone acetonide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete